Table 2.
Tumor response as assessed by blinded independent central review using RECIST 1.1
| Benmelstobart + anlotinib + EC group (N = 246) | Anlotinib + EC group (N = 245) | EC alone group (N = 247) | |
|---|---|---|---|
| Objective confirmed response | |||
| No. of patients | 200 (81.3) | 199 (81.2) | 165 (66.8) |
| 95% CI | 75.9–86.0 | 75.8–85.9 | 60.6–72.6 |
| P value | 0.0001 | 0.0003 | Reference |
| Best objective response, no. (%) | |||
| CR | 3 (1.2) | 1 (0.4) | 0 |
| PR | 197 (80.1) | 198 (80.8) | 165 (66.8) |
| SD | 23 (9.3) | 28 (11.4) | 50 (20.2) |
| PD | 8 (3.3) | 3 (1.2) | 16 (6.5) |
| NEa | 15 (6.1) | 15 (6.1) | 16 (6.5) |
Differences in response rate between the treatment groups were assessed with the stratified Cochran–Mantel–Haenszel test. P values are two-sided.
aThe best overall response could not be evaluated for patients who had no baseline or no postbaseline tumor assessments and at least one lesion that could not be evaluated.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated.